The groundbreaking success of Viagra undeniably reshaped the pharmaceutical landscape, but investing in companies heavily reliant on unbranded versions presents a challenging picture. Although early returns were significant, the cessation of patents and the rise of discounted alternatives have weakened sales. Thus, a thorough assessment of ongoing